MOTS-c (Mitochondrial Peptide)

The Structural Reasons the Evidence Is Thin

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

MOTS-c has no identified receptor, an unresolved question about where it is translated, a mechanism described as indirect, and two oxidation-prone residues. Each of these is a structural obstacle to producing the kind of evidence the field would want.

Key facts

Receptor
None identified
Site of translation
Not settled
Mechanism
Indirect, via folate cycle and AMPK
Chemistry
Two oxidation-prone methionines
Human data
Correlational
Interventional trials
None established

No receptor means no standard toolkit

A defined receptor gives a field its instruments: binding assays, dose-response curves, selective antagonists to prove that an observed effect runs through the proposed pathway. Without one, an effect can be measured but not readily attributed. This is the same gap that has kept DSIP unresolved for nearly fifty years, and it is the single most limiting feature here.

The translation question is upstream of everything

Mitochondrial and nuclear genetic codes differ, so the same reading frame produces different peptides depending on which ribosomes read it. For a mitochondrially encoded peptide, that is not a detail. It determines what the endogenous molecule actually is. A synthetic peptide made to one interpretation may not match what a cell produces.

Research material referenced

MOTS-C 10mg, third-party HPLC tested

Buy MOTS-C · £24.99

An indirect mechanism is harder to test

The described route runs through the folate cycle to an intermediate that activates AMPK, rather than through direct receptor engagement. Indirect mechanisms are scientifically interesting and experimentally awkward, because every step between the compound and the readout is somewhere the causal chain can break or be confounded.

The chemistry adds a practical layer

Two methionines at 12.5% of the sequence oxidise readily, producing +16 and +32 Da species. A preparation that has partly oxidised is not the compound specified, and if oxidation state is not checked it becomes an uncontrolled variable across experiments. That is a mundane obstacle and it is a real one.

Why the human evidence stays correlational

Measuring circulating levels and relating them to exercise or metabolic state produces associations. Turning those into causal claims requires intervention, and no established human interventional programme exists. The ceiling on the human data is a consequence of what has been done, not of what could be.

What would move it forward

An identified receptor or binding partner. Resolution of where translation occurs. Controlled human intervention. None of these is impossible and none has happened, and being clear about that is more useful than the promising framing that surrounds this compound. Material supplied here is for laboratory research only.

Frequently asked questions

Does MOTS-c have a known receptor?

No. Without one, effects can be measured but are difficult to attribute to a specific pathway.

Why does the site of translation matter?

Mitochondrial and nuclear genetic codes differ, so the same reading frame yields different peptides depending on which ribosomes read it.

Is there human interventional data?

No established programme. Human observations are correlational. Measured levels related to exercise or metabolic state.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More MOTS-c (Mitochondrial Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.